CureVac has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. under which CureVac will collaborate with Crucell Holland B.V. (a Janssen Pharmaceutical member company) on the development of an flu vaccine based on CureVac's RNActive technology. CureVac's technology platform with RNActive vaccines has demonstrated effectiveness and safety in several clinical trials.
CureVac will develop optimized RNActive vaccines based on Crucell's proprietary antigen sequences, which will be tested in various models. Additional details were not disclosed.
CureVac, Crucell in Flu Vax Development Pact
Published October 3, 2013
blog comments powered by Disqus